NCT03229096UnknownPhase 2
Apatinib Plus XELOX Regime as Neoadjuvant Therapy in Locally Advanced Gastric Cancer Patients With Lymph Node Metastasis
Shanghai Zhongshan Hospital1 site in 1 country35 target enrollmentStarted: February 1, 2017Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Sponsor
- Enrollment
- 35
- Locations
- 1
- Primary Endpoint
- Objective response rate (ORR)
Study Overview
Brief Summary
Apatinib plus XELOX regime as Neoadjuvant Therapy in Locally Advanced Gastric Cancer PatientsWith lymph node metastasis
Detailed Description
This is a Single-center, Open-label, Single-arm,Non-randomized exploratory clinical trial evaluating the efficacy and safety of Apatinib plus XELOX regime as Neoadjuvant Therapy in Locally Advanced Gastric Cancer Patients With lymph node metastasis
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Adult patients, age ≥18 years.
- •Karnofsky score 70%.
- •Histologically confirmed adenocarcinoma of gastric cancer with Lauren classification Clinically diagnosed stage T2-T4aN+M0 according to CT/MRI scan.
- •At least one measurable and evaluable disease based on response evaluation criteria in solid tumors (RECIST v1.1), that is one or more perigastric lymph note were greater than or equal to 1.5cm in diameter.
- •Laparoscopic exploration confirms no peritoneal metastasis and negative peritoneal lavage.
- •Physical condition and adequate organ function to ensure the success of abdominal surgery.
- •Adequate hematological function: Neutrophil count ≥ 1.5 × 109/L, Platelets ≥ 100 × 109/L and Hemoglobin ≥8g/dL. Adequate liver function: Total bilirubin ≤ 1.5 × upper limit of normal (ULN); AST (SGOT) and ALT (SGPT) < 2.5 × ULN. ALP ≤ 2.5 × upper limit of normal (ULN); ALB ≥30g/L.Adequate renal function: Serum creatinine ≤ 1 x ULN, and serum albumin≥30g/L.
- •Life expectancy of more than 5 years without serious concomitant diseases.
- •Written (signed) informed consent.
- •Able to comply with study and follow-up procedures.
- •Consent to provide tissue sample.
Exclusion Criteria
- •Pregnant or lactating women.
- •pregnancy tests before entering the group (in serum) of the childbearing age women were positive, or no pregnancy tests.
- •patients with distant metastases or local unresectable factors.
- •tumor stage considered as cT1 by imaging or ultrasound gastroscopy.
- •Patients who received prior anti-tumor therapy including cytotoxic chemotherapy, radiotherapy, hormonal therapy and immunotherapy.
- •History of other malignancies within the last 5 years except cured basal cell carcinoma of skin and carcinoma in situ of uterine cervix.
- •History of significant neurological or mental disorder, including seizures or dementia, which may interfere compliance and sign of consent inform.
- •Unstable, persistent cardiac disease despite medicinal treatment; myocardial infarction within 12 months before the start of the trial.
- •Patients with poor-controlled arterial hypertension (systolic pressure ≥ 140 mmHg and/or diastolic pressure ≥ 90 mm Hg) despite standard medical management.
- •Ileus, chronic inflammatory intestinal disease or extensive resection of the small intestine and other disorders which limit drug absorption.
- •Patients who experienced GI bleeding within two weeks, or with high risk of bleeding.
- •Patients with symptomatic peripheral neuropathy NCI CTC version> 1.0 grade, except only the deficiency of Deep tendon reflex.
- •Organ transplant patient need immunosuppression treatment.
- •Active or uncontrolled severe infection or other severe and /or uncontrolled diseases
- •Patients with moderate or severe chronic kidney disease estimated glomerular filtration rate≤50 ml/min or serum creatinine ≥the upper limit of normal(ULN),
- •deficiency of dihydropyrimidine dehydrogenase (DPD)
- •Allergy to the drugs in this protocol
- •Less than 4 weeks from the last clinical trial.
Arms & Interventions
Apatinib plus XELOX
Experimental
Patients will be given the perioperative chemotherapy of Apatinib plus XELOX once recruited
Intervention: Apatinib plus XELOX (Drug)
Outcomes
Primary Outcomes
Objective response rate (ORR)
Time Frame: 3 months
Both CR and PR according to Response Evaluation Criteria in Solid Tumors RECIST Version 1.1
Secondary Outcomes
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability](30 days)
- Pathological response rate (pRR)(30 days)
- 3-year disease free survival rate(3 years)
- 3-year overall survival rate(3 years)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Unknown
Phase 2
Comparison Between XELOX and S1, Oxaliplatin and Docetaxel as Neoadjuvant Chemotherapy for Gastric CancerGastric CancerNCT02623153Tianshu Liu200
Completed
Phase 2
Trial of Xeloda and Oxaliplatin (XELOX) as Neo-adjuvant Chemotherapy Followed by Surgery in Advanced Gastric Cancer Patients With Para-aortic Lymph Node MetastasisAdvanced Gastric CancerNCT02071043Shanghai Zhongshan Hospital48
Unknown
Phase 3
Neoadjuvant SLOT Versus SOX in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EGJ) CancerGastric AdenocarcinomaNCT02512380Chinese Academy of Medical Sciences380
Unknown
Phase 2
Receiving Modified Chemotherapy Followed With Radical Resection After Neoadjuvant ChemotherapyLocally Advanced Gastric CancerNCT03322969Peking Union Medical College Hospital60
Completed
Phase 2
Chemotherapy Combined With Apatinib and PD-1 AntibodyGastric CancerNCT05025033Tianjin Medical University Cancer Institute and Hospital30